GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (NAS:ENLV) » Definitions » Cyclically Adjusted Book per Share

Enlivex Therapeutics (Enlivex Therapeutics) Cyclically Adjusted Book per Share : $24.80 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Enlivex Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Enlivex Therapeutics's adjusted book value per share for the three months ended in Dec. 2023 was $1.618. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $24.80 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Enlivex Therapeutics's average Cyclically Adjusted Book Growth Rate was -1.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-05-26), Enlivex Therapeutics's current stock price is $1.40. Enlivex Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $24.80. Enlivex Therapeutics's Cyclically Adjusted PB Ratio of today is 0.06.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Enlivex Therapeutics was 0.17. The lowest was 0.00. And the median was 0.00.


Enlivex Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Enlivex Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enlivex Therapeutics Cyclically Adjusted Book per Share Chart

Enlivex Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 25.16 24.80

Enlivex Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.16 25.65 25.27 24.86 24.80

Competitive Comparison of Enlivex Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Enlivex Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enlivex Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enlivex Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Enlivex Therapeutics's Cyclically Adjusted PB Ratio falls into.



Enlivex Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Enlivex Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.618/129.4194*129.4194
=1.618

Current CPI (Dec. 2023) = 129.4194.

Enlivex Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.000 99.695 0.000
201406 10.585 100.560 13.623
201409 93.867 100.428 120.965
201412 86.221 99.070 112.635
201503 78.972 99.621 102.594
201506 70.640 100.684 90.801
201509 62.143 100.392 80.111
201512 50.405 99.792 65.370
201603 56.721 100.470 73.064
201606 37.793 101.688 48.100
201609 27.748 101.861 35.255
201612 21.228 101.863 26.971
201703 15.296 102.862 19.245
201706 11.303 103.349 14.154
201709 8.966 104.136 11.143
201712 7.568 104.011 9.417
201803 0.000 105.290 0.000
201806 3.715 106.317 4.522
201809 0.000 106.507 0.000
201812 21.833 105.998 26.657
201903 1.363 107.251 1.645
201906 1.519 108.070 1.819
201909 1.334 108.329 1.594
201912 1.092 108.420 1.304
202003 2.387 108.902 2.837
202006 2.242 108.767 2.668
202009 2.117 109.815 2.495
202012 2.433 109.897 2.865
202103 4.950 111.754 5.732
202106 4.928 114.631 5.564
202109 4.805 115.734 5.373
202112 4.639 117.630 5.104
202203 4.226 121.301 4.509
202206 3.726 125.017 3.857
202209 3.437 125.227 3.552
202212 3.086 125.222 3.189
202303 2.724 127.348 2.768
202306 2.385 128.729 2.398
202309 2.085 129.860 2.078
202312 1.618 129.419 1.618

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Enlivex Therapeutics  (NAS:ENLV) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Enlivex Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.40/24.8
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Enlivex Therapeutics was 0.17. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Enlivex Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Enlivex Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Enlivex Therapeutics (Enlivex Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
14 Einstein Street, Nes Ziona, ISR, 7403618
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Enlivex Therapeutics (Enlivex Therapeutics) Headlines

From GuruFocus